For more information, visit the Nova One Advisor website or email the team at ... | Call us: +1 804 420 9370

What are the Key trends in the Plasma Fractionation Market in 2024?

• In September 2024, London-based biotech leader Epsilogen secured $16.4 million in a funding round to advance the development of its immunoglobulin E (IgE) antibodies for cancer therapy. The investment came from British Patient Capital, Novartis Venture Fund, Epidarex Capital, 3B Future Health Fund, and ALSA Ventures.
• In June 2024, Biotest, a global plasma protein and biotherapeutics provider under Grifols, received FDA approval to market Yimmugo, a therapy for primary humoral immunodeficiency (PI) in patients aged two years and above.

What are the Emerging Challenges in the Plasma Fractionation Market?

The market faces challenges, including limited plasma supply, high costs of collection and processing, and strict regulatory requirements for safety and quality. Additionally, technological complexities in fractionation, risk of contamination, and dependence on donor availability hinder growth. Market expansion is also affected by competition from alternative therapies and the need for continuous investment in advanced infrastructure and research to meet rising global demand for plasma-derived products.

Segmental Insights

By Type Insights

How did the Immune Globulin Segment Dominate the Plasma Fractionation Market in 2024?

In 2024, the immune globulin segment held the largest market share due to its widespread use in treating immune deficiencies, autoimmune diseases, and neurological disorders. Growing awareness of immunoglobulin therapies, increased prevalence of immunodeficiency conditions, and rising demand for intravenous and subcutaneous formulations contributed to this dominance. Moreover, ongoing product innovations, improved manufacturing, and strengthened the segment's position in the global plasma fractionation market.

The coagulation factor segment is expected to grow at the fastest CAGR due to the increasing prevalence of bleeding disorders such as hemophilia and von Willebrand disease. Advancements in recombinant technologies and plasma-derived factor concentrates are enhancing treatment effectiveness and safety. Rising awareness, improved diagnostic facilities, and greater access to specialized therapies are further fueling demand. Additionally, government initiatives and healthcare investments aimed at managing rare blood disorders are accelerating this segment's growth.

Plasma Fractionation Market Size by Type, 2024 to 2034 (USD Billion)

By Application Insights

What made the Hospital Segment Dominant in the Plasma Fractionation Market in 2024?

In 2024, the hospital segment dominated the plasma fractionation market due to the high volume of patient admissions requiring plasma-derived therapies for critical conditions like immune deficiencies, bleeding disorders, and liver diseases. Hospitals serve as primary centers for transfusion, diagnostics, and advanced therapeutic procedures. The availability of skilled healthcare professionals, well-established infrastructure, and advanced treatment facilities further supported hospitals' leading role in plasma product usage and overall market share.

The retail pharmacy segment is projected to grow at the fastest CAGR due to increasing patient preference for convenient access to plasma-derived medicines outside hospital settings. Expanding distribution networks, improved drug availability, and rising awareness of home-based treatments are driving this growth. Additionally, partnerships between manufacturers and pharmacy chains, along with supportive healthcare policies and rising chronic disease cases, are enhancing the retail channel's role in delivering plasma-based therapies efficiently.

Plasma Fractionation Market Size by Application, 2024 to 2034 (USD Billion)

By Regional Analysis

How is North America contributing to the Expansion of the Plasma Fractionation Market?

In 2024, North America dominated the market due to its strong healthcare infrastructure, high plasma collection rates, and advanced manufacturing capabilities. The region's leadership is supported by the presence of major industry players, favorable regulatory frameworks, and significant investments in research and development. Additionally, growing demand for plasma-derived therapies, increased awareness of immunodeficiency and bleeding disorders, and well-established reimbursement systems further strengthened North America's market position.

How is Asia-Pacific Accelerating the Plasma Fractionation Market?

The Asia-Pacific region is expected to record the fastest CAGR in the market due to rising healthcare investments, expanding awareness of plasma-derived therapies, and increasing prevalence of chronic and rare diseases. Growing plasma collection activities, supportive government initiatives, and improving healthcare infrastructure across countries like China, India, and Japan are driving regional growth. Additionally, the presence of emerging biopharmaceutical companies and rising demand for affordable treatment options are fueling market expansion.

Plasma Fractionation Market Size By Regional, 2024 to 2034 (USD Billion)

Top Companies in the Plasma Fractionation Market

• Syntegon
• CSL Behring
• Mitsubishi Tanabe
• Octapharma AG
• Hualan Bio
• Kedrion S.p.A
• Takeda Pharmaceutical Company Ltd.
• LFB Group
• Intas Pharmaceuticals Ltd.
• Biotest AG
• Bio Product Laboratory Ltd.
  

  Recent Developments in the Plasma Fractionation Market

  • In August 2024, Nanoform Finland partnered with Takeda Pharmaceutical Company to develop pre-clinical plasma-derived therapies aimed at treating rare diseases, focusing on improving drug formulations and therapeutic performance.
  • In September 2024, GEFD, a joint venture between Grifols and Egypt's National Service Project Organization (NSPO), launched a national initiative to achieve self-sufficiency in plasma-derived medicines. The project includes a plasma lab, storage facility, 20 donation centers, and an advanced manufacturing plant.

  More Insights in Nova One Advisor:

  • AI in Life Sciences Market - The global artificial intelligence (AI) in life sciences market.
  • Dental Implants Market - The global dental implants market size
  • Targeted DNA RNA Sequencing Market - The global targeted DNA RNA sequencing market
  • U.S. Dental Services Market - The US dental services market size
  • U.S. Livestock Monitoring Market - The U.S. livestock monitoring market
  • In Vitro Fertilization (IVF) Services Market - The global in vitro fertilization (IVF) services market size
  • Life Sciences IT Market - The global life sciences IT market size
  • U.S. Humidifiers Market - The U.S. humidifiers market size
  • Digital Manufacturing in Life Sciences Market - The global digital manufacturing in life sciences market size
  • Middle East AI In Patient Engagement Market - The Middle East patient engagement solutions market size
  • Middle East Cosmetic Surgery & Procedure Market - The Middle East cosmetic surgery and procedure market size
  • Full Service CRO Market - The global full service CRO market size
  • CRISPR Technology Market - The global CRISPR technology market size
    

  Plasma Fractionation Market Report Segmentation

  This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2019 to 2034. For this study, Nova One Advisor has segmented the global Plasma Fractionation Market

  By Type

  • Albumin
  • Immune Globulin
  • Coagulation Factor
  • Others

  By Application

  • Hospital
  • Retail Pharmacy
  • Other
    

  By Regional

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
    
  Immediate Delivery Available | Buy This Premium Research Report (Global Deep Dive USD 3800)

  About-Us

  Nova One Advisor is a global leader in market intelligence and strategic consulting, committed to delivering deep, data-driven insights that power innovation and transformation across industries. With a sharp focus on the evolving landscape of life sciences, we specialize in navigating the complexities of cell and gene therapy, drug development, and the oncology market, enabling our clients to lead in some of the most revolutionary and high-impact areas of healthcare.

  Our expertise spans the entire biotech and pharmaceutical value chain, empowering startups, global enterprises, investors, and research institutions that are pioneering the next generation of therapies in regenerative medicine, oncology, and precision medicine.

  Our Trusted Data Partners

  Towards Chemical and Materials | Precedence Research | Statifacts | Towards Packaging | Towards Healthcare | Towards Food and Beverages | Towards Automotive | Towards Consumer Goods | Nova One Advisor | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics | Towards Chem and Material
  Web:

  Contact Us

  USA: +1 804 420 9370

  Email: ...
  For Latest Update Follow Us: LinkedIn